Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2026-08-13 21:00:08 ET · period of report 2026-08-12 · accession 0001193125-26-349962 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-13 21:00 | 2026-08-12 | WVE | Rawcliffe Adrian | Dir | S - Sale | $5.29 | -12.7K | 0 | -100% | -$67.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-12 | S | D | 12,700 | $5.29 | 0 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. (F2) The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |